ASTHMA AND COPD MARKET ANALYSIS

The Global Asthma And COPD Market is estimated to be valued at US$ 35.2 Bn in 2023 and is expected to exhibit a CAGR of 4.9% during the forecast period (2023-2030).

Analysts’ Views on Global Asthma And COPD Market :

Increasing number of drug development and drug discovery activities are expected to boost the growth of the global asthma and COPD market over the forecast period. For instance, according to the data published on May 3, 2023, in The Journal of Asthma and Allergy, an international, peer-reviewed journal encompassing all aspects of diagnosis, epidemiology, prevention, management, and treatment of asthma and allergic disease, baseline asthma characteristics did not adversely affect outcomes among patients who received dupilumab for their comorbid chronic rhinosinusitis with nasal polyps (CRSwNP). The monoclonal antibody improved patient outcomes in both chronic diseases.

Figure 1. Global Asthma And COPD Market Share (%), by Drug Type, 2023

To learn more about this report, request a free sample copy

Global Asthma And COPD Market– Driver

Increasing research & development activities in the asthma and COPD field

The growing research & development activities a major factor leading to the high demand for asthma and COPD drug treatments. For instance, on May 23, 2023, a clinical trial conducted  by AstraZeneca, a global, science-led biopharmaceutical business, showed that initiating fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate) within 30 days of a qualifying moderate or severe exacerbation in patients with COPD (chronic obstructive pulmonary disease), is associated with a decreased risk of future exacerbations by 24%.

Expansion of manufacturing facilities regarding asthma and COPD drug treatments

The expansion of production & manufacturing facilities to produce newer drug therapies can drive the growth of the global asthma and COPD market. For instance, in October 2021,  Honeywell, a publicly traded, multinational conglomerate corporation,  announced the opening of a plant in Louisinia, U.S., that is the company’s first large-scale manufacturing site for Solstice Air, a near-zero global-warming-potential (GWP) medical propellant for use in respiratory inhalers.

Figure 2. Global Asthma And COPD Market Value (%), by Region, 2023

To learn more about this report, request a free sample copy

Global Asthma And COPD Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global asthma and COPD market over the forecast period. This is due to the increasing number of research & development activities in the region. For instance, according to the data published by American researchers in The Journal of Medicinal Chemistry, a U.S.-based biweekly peer-reviewed medical journal covering research in medicinal chemistry, on March 13, 2023, activating the taste receptors that are located all over the body, opens up lung passageways. Hence, they are a potential target for treating asthma or chronic obstructive pulmonary disease (COPD).

Global Asthma And COPD Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a positive impact on the global asthma and COPD market. According to an article published in February 2021, in Nature, a weekly scientific Journal founded and based in London, England, among the COVID-19 patients in South Korea, the risk for all-cause mortality was approximately two times higher in patients with COPD than in those without COPD. Among the COVID-19 patients who were 40 years and older, 3.1% had COPD; of these, 7.1% received ICU care, and 5.7% received mechanical ventilation.

Global Asthma And COPD Market Segmentation:

The global asthama and COPD market report is segmented into drug type, disease type, distribution channel,  and region.

By Drug Type, the market is segmented into bronchodilators, anti-inflammatories and combination therapies. Out of which, the bronchodilators segment is expected to hold a dominant position in the global asthama and COPD market during the forecast period and this is attributed to its targeted drug delivery.

By Disease Type, the market is segmented into asthma and COPD. Out of which, the asthma segment is expected to hold a dominant position in the global asthama and COPD market during the forecast period and this is attributed to the increasing prevalence of the disease globally.

By Distribution Channel, the market is segmented hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital pharmacy segment is expected to dominate the market over the forecast period and this is attributed to the increasing hospitalizations caused by respiratory disorders all over the world.

By Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. Out of which, the North America segment is expected to dominate the market over the forecast period and this is attributed to the increased research & development activities in the region.

Among all the segmentations, the disease type segment has the highest potential due to the increasing prevalence of the disease. For instance, according to the  data shared on November 23,  2020, by Cleaveland Clinic, a non-profit system of public hospitals, in the U.S., as of 2020, about 25 million people were suffering from  asthma. Out of which, approximately 60% had asthma that is caused by allergies.

Global Asthma And COPD Market Cross Sectional Analysis:

Among drug type, bronchodilators segment is expected to show maximum growth in Asia Pacific region due to the increased product launches regarding asthma and COPD drug treatments. For instance, on January 3, 2023, Lupin, an India-based pharmaceuticals firm, announced that it had launched a fixed-dose triple drug combination of 3 bronchodilators-  Indacaterol, Glycopyrronium, and Mometasone, for managing asthma.

Global Asthma And COPD Market: Key Developments

 In February 2020, Sunshine Guojian Pharmaceutical(Shanghai)Co.,Ltd, a China-based biopharmaceutical company, approved to start clinical trial of new Anti-IL-5 monoclonal antibody drug for treatment of asthma in China.

In June 2020, Novartis Pharma K.K, the Japan business of strategic alliance partner Novartis AG, a Switzerland-based multinational pharmaceutical comapany, announced the manufacturing and marketing approval for its Enerzair Inhalation Capsules (medium-dose and high-dose) in Japan as a treatment of bronchial asthma.

In August 2022, Upstream Bio, a U.S.-based drug developer, initiated a Phase Ib multiple ascending dose study of UPB-101 in asthma patients and successful dosing of the first patient. UPB-101 is a monoclonal antibody designed to block the thymic stromal lymphopoietin receptor (TLSPR) and thus inhibit TSLP-driven inflammation. TSLP is a cytokine and a key driver of inflammatory response in asthma and other allergic and inflammatory diseases.

On 9 February 2022, Generium, a Russia-based pharmaceutical company, announced the launch of Omalizumab in Russia, under the brand name Genolar. Genolar is a recombinant humanized IgG1k monoclonal antibody that binds to free human immunoglobulin E (IgE). The product is available in Russia for the treatment of persistent atopic bronchial asthma (the most common form of asthma) in patients aged 6 and older.

Global Asthma And COPD Market: Key Trends

The increasing drug discovery and drug development activities provide lucrative opportunities for the growth of the asthma and COPD market. In July 2022, AstraZeneca, a biopharmaceutical company’s drug- Tezspire (tezepelumab) was recommended for marketing authorisation in the European Union (EU) as an add-on therapy in patients 12 years and older with severe asthma. Tezspire acts at the top of the inflammatory cascade by blocking thymic stromal lymphopoietin (TSLP), an epithelial cytokine.Tezspire consistently and significantly reduced asthma exacerbations across Phase II and III clinical trials, which included a broad population of severe asthma patients.

The rising avent of partnerships, mergers, and agreement scenarios can provide lucrative opportunities for the growth of the global asthma and COPD market. For instance, in July 2022, Knopp Biosciences LLC, a privately held company managing a portfolio of equity securities and future product royalties, and Population Health Partners, an investment company focused on innovative therapeutics with the potential to transform health outcomes for populations, announced the establishment of Areteia Therapeutics, a new clinical-stage medical company focused on putting asthma patients in better control of its disease with the first potential oral therapy for eosinophilic asthma.

Global Asthma And COPD Market: Restraint

Product Recalls

The production and manufacturing faults leading to the recall of products  can restrain the growth of the global asthma and COPD market. For instance, in October 2022, Cipla, a multinational pharmaceutical company, recalled 9,041 cartons of Arformoterol Tartrate Inhalation Solution, which is used to help control the symptoms of Chronic Obstructive Pulmonary Disease (COPD).

This restrain can be overcome by adopting Good Manufacturing Practices (GMP) and observing strict compliance with regulatory guidelines.

Potential side-effects of steroid inhalers

Taking a high dose of steroid inhalers for a long time, can cause side effects such as an increased appetite, mood changes, and difficulty in sleeping. Some patients over the years have reported a sore mouth, a hoarse voice, and coughs. Taking high doses of corticosteroids for a long time can slow down the normal growth of children and teenagers.

This restrain can be overcome by the using the steroid inhalers correctly at low doses.

Global Asthma And COPD Market- Key Players

Major players operating in the global asthma and COPD market include AstraZeneca, Novartis AG, GSP plc, Merck & Co., Inc., Verona Pharma plc, Regeneron Pharmaceuticals Inc., and Boehringer Ingelheim International GmbH.

*Definition: Asthma and chronic obstructive pulmonary disease (COPD) are lung diseases. Both cause swelling in a patient’s airways that makes it hard to breathe. With asthma, the swelling is often triggered by something a person is allergic to, like pollen or mold, or by physical activity. COPD is the name given to a group of lung diseases that include emphysema and chronic bronchitis.